Finally, we probed the role of HLA-G/KIR2DL4 in the response of clinical breast cancer to trastuzumab using neoplastic specimens of trastuzumab-resistant and trastuzumab-sensitive patients (Table 2). Here, HLA-G is linked to breast carcinoma.